4//SEC Filing
MORTIMER IAN 4
Accession 0000950170-25-039025
CIK 0001582313other
Filed
Mar 12, 8:00 PM ET
Accepted
Mar 13, 7:33 PM ET
Size
7.4 KB
Accession
0000950170-25-039025
Insider Transaction Report
Form 4
MORTIMER IAN
DirectorPRESIDENT & CEO
Transactions
- Award
Restricted Share Units
2025-03-12+50,000→ 50,000 totalExercise: $0.00→ Common Shares (50,000 underlying) - Award
Share Option (Right to Buy)
2025-03-12+275,000→ 275,000 totalExercise: $35.48Exp: 2035-03-11→ Common Shares (275,000 underlying)
Footnotes (2)
- [F1]Vesting 25% on March 12, 2026, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
- [F2]Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026.
Documents
Issuer
Xenon Pharmaceuticals Inc.
CIK 0001582313
Entity typeother
Related Parties
1- filerCIK 0001619961
Filing Metadata
- Form type
- 4
- Filed
- Mar 12, 8:00 PM ET
- Accepted
- Mar 13, 7:33 PM ET
- Size
- 7.4 KB